FibroGen
Another Phase 3 flop for FibroGen as DMD drug fails to improve mobility
Anika Sharma
FibroGenās troubles continue to mount. The biotech announced its fourth phase 3 failure in four months after the market closed ...
FibroGen CEO Conterno Resigns Amid Roxadustat Launch Setbacks
SG Tylor
Source – FibroGen Enrique Conterno, who became FibroGen’s CEO in early 2020, had high hopes for the anemia drug roxadustat ...
